Who is Not a Good Candidate for MRSA Prodrug TXA709?
SEP 03, 2017 | CONTAGION® EDITORIAL STAFF
Daniel Pilch, PhD, associate professor, Rutgers Robert Wood Johnson Medical School, explains which patients would not make good candidates for MRSA prodrug TXA709. Dr. Pilch shares that TXA709 is capable of treating life-threatening bloodstream infections as well as skin and soft tissue infections. MRSA is also known for infecting bone; although distribution studies suggest that the drug can treat bone infections, more research still needs to be done.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
We break down our top HIV news stories of 2017. Did you read them all?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512